Expression of gp200-MR6 in Breast Tumors
Author Information
Author(s): AA Al-Tubuly, YA Luqmani, S Shousha, D Melcher, MA Ritter
Primary Institution: Royal Postgraduate Medical School, Hammersmith Hospital
Hypothesis
Does the expression of gp200-MR6 correlate with tumor progression in breast cancer?
Conclusion
The study found that gp200-MR6 is expressed in normal and benign breast tissues but is lost in invasive breast carcinomas.
Supporting Evidence
- gp200-MR6 is expressed at high levels in normal breast tissue.
- Expression of gp200-MR6 is lost in 71% of invasive carcinoma cases.
- Benign hyperplasia shows heterogeneous expression of gp200-MR6.
Takeaway
This study looked at a molecule called gp200-MR6 in breast tissues and found that it is present in healthy and benign tissues but mostly absent in cancerous tissues.
Methodology
Immunohistochemical and biochemical analysis of fresh frozen tissue samples from breast tissues.
Limitations
The inability to detect gp200-MR6 in formalin-fixed paraffin-embedded tissues limited the sample size for benign hyperplasia.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website